🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Public Health Issue

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million infections per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices currently available.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, alternatively called a brand name, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the drug firm its industry partner to develop it.

“This authorization represents a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Results and Global Access

According to data released by a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which involves a dual-drug approach. The research enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of developing nations.

Medical professionals directly involved have expressed positive views. Access to a single-dose, oral treatment such as this is hailed as a "critical tool" for managing the epidemic. This is considered crucial to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea globally.